RISPERIDONE DEPOT showed no clear difference in adverse events: Movement disorder ‐ any extra pyramidal symptoms ‐… compared with ORAL RISPERIDONE (moderate certainty).
RISPERIDONE DEPOT showed no clear difference in adverse events: Specific ‐ prolactin‐related compared with ORAL RISPERIDONE (moderate certainty).
RISPERIDONE DEPOT probably leads to lower leaving the study early: Any reason ‐ long term compared with ORAL QUETIAPINE (moderate certainty).
RISPERIDONE DEPOT showed no clear difference in adverse events: General ‐ serious Recorded at each compared with ORAL QUETIAPINE (low certainty).
RISPERIDONE DEPOT may leads to higher adverse events: Movement disorder ‐ any extra pyramidal symptom compared with ORAL QUETIAPINE (low certainty).
RISPERIDONE DEPOT may leads to higher adverse events: Specific ‐ prolactin‐related Reported by… compared with ORAL QUETIAPINE (low certainty).
RISPERIDONE DEPOT showed no clear difference in global state: Relapse (any reason) ‐ long term Assessed by 5 blinded… compared with ORAL ARIPIPRAZOLE (low certainty).
It is very uncertain whether RISPERIDONE DEPOT changes leaving the study early: Any reason ‐ long term compared with ORAL ARIPIPRAZOLE (very low certainty).
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: General ‐ serious Unclear how these events were… compared with ORAL ARIPIPRAZOLE (very low certainty).
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Movement disorder ‐ any extra pyramidal symptoms compared with ORAL ARIPIPRAZOLE (very low certainty).
RISPERIDONE DEPOT showed no clear difference in adverse events: Specific ‐ weight increase compared with ORAL ARIPIPRAZOLE (low certainty).
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Specific ‐ prolactin‐related compared with ORAL ARIPIPRAZOLE (very low certainty).
RISPERIDONE DEPOT may leads to higher leaving the study early: Any reason ‐ long term compared with ORAL OLANZAPINE (low certainty).